Eidos Therapeutics Inc (NASDAQ:EIDX) insider Jonathan C. Fox sold 5,000 shares of the business’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $23.11, for a total value of $115,550.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.
Shares of EIDX opened at $25.01 on Wednesday. Eidos Therapeutics Inc has a 12-month low of $8.89 and a 12-month high of $25.55.
Eidos Therapeutics (NASDAQ:EIDX) last issued its quarterly earnings results on Monday, April 15th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.01). As a group, equities research analysts predict that Eidos Therapeutics Inc will post -1.3 earnings per share for the current year.
Several equities analysts recently issued reports on EIDX shares. JPMorgan Chase & Co. upgraded Eidos Therapeutics from a “neutral” rating to an “overweight” rating in a research note on Wednesday, February 27th. BMO Capital Markets started coverage on Eidos Therapeutics in a research note on Friday, February 22nd. They set an “outperform” rating and a $28.00 price target on the stock. Finally, Zacks Investment Research lowered Eidos Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, April 9th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $27.00.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Wexford Capital LP boosted its holdings in Eidos Therapeutics by 100.0% during the fourth quarter. Wexford Capital LP now owns 40,000 shares of the company’s stock valued at $550,000 after purchasing an additional 20,000 shares in the last quarter. BlackRock Inc. boosted its holdings in Eidos Therapeutics by 385.1% during the third quarter. BlackRock Inc. now owns 727,698 shares of the company’s stock valued at $7,264,000 after purchasing an additional 577,698 shares in the last quarter. Vanguard Group Inc boosted its holdings in Eidos Therapeutics by 297.3% during the third quarter. Vanguard Group Inc now owns 198,673 shares of the company’s stock valued at $1,983,000 after purchasing an additional 148,673 shares in the last quarter. Aisling Capital Management LP acquired a new stake in Eidos Therapeutics during the fourth quarter valued at approximately $15,461,000. Finally, Fosun International Ltd acquired a new stake in Eidos Therapeutics during the fourth quarter valued at approximately $1,308,000. 30.15% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: This piece of content was published by Macon Daily and is the sole property of of Macon Daily. If you are accessing this piece of content on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this piece of content can be accessed at https://macondaily.com/2019/04/17/eidos-therapeutics-inc-eidx-insider-sells-115550-00-in-stock.html.
Eidos Therapeutics Company Profile
Eidos Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR.
Recommended Story: What factors cause inflation to rise?
Receive News & Ratings for Eidos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eidos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.